Estrogen receptors: Therapies targeted to receptor subtypes

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 44-55

  Nilsson, S ^a,b   Gustafsson, J A ^b,c  

^a Karo Bio   (Sweden)

^b Department of Biosciences and Nutrition ^*  (Sweden)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16 ALPHA LE2; 8 BETA VE2; AROMATASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 19; ESTROGEN RECEPTOR BETA; LIQUIRITIGENIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PPT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG; WAY 200070;

ARTICLE; ATHEROSCLEROSIS; BONE MATURATION; BONE METABOLISM; BREAST; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEGENERATIVE DISEASE; DEPRESSION; DRUG MECHANISM; DRUG TARGETING; HOMEOSTASIS; HUMAN; MULTIPLE SCLEROSIS; NEOPLASM; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN STRUCTURE; UROGENITAL SYSTEM; VASOMOTOR REFLEX;

ANIMALS; DRUG DESIGN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; MALE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 78650446029     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.226     Document Type: Article

References (50)

1. Nilsson, S. & Gustafsson, J.-Å. Estrogen receptors: their actions and functional roles in health and disease. In Nuclear Receptors: Current Concepts and Future Challenges (eds. Bunce, C. & Campbell, M.J.) 91-141 (Springer, The Netherlands, 2010).
2. Levin, E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab. 20, 477-482 (2009).
3. Maggiolini, M. & Picard, D. The unfolding stories of GPR30, A new membrane-bound estrogen receptor. J. Endocrinol. 204, 105-114 (2010).
4. Ascenzi, P., Bocedi, A. & Marino, M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med. 27, 299-402 (2006).
5. Lonard, D.M. & O'Malley, B.W. The expanding cosmos of nuclear receptor coactivators. Cell 125, 411-414 (2006).
6. Perissi, V. & Rosenfeld, M.G. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat. Rev. Mol. Cell Biol. 6, 542-554 (2005).
7. Bramlett, K.S., Wu, Y. & Burris, T.P. Ligands specify coactivator nuclear receptor (NR) box afnity for estrogen receptor subtypes. Mol. Endocrinol. 15, 909-922 (2001).
8. McInerney, E.M., Tsai, M.J., O'Malley, B.W. & Katzenellenbogen, B.S. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc. Natl. Acad. Sci. U.S.A. 93, 10069-10073 (1996).
9. Reid, G., Gallais, R. & Métivier, R. Marking time: the dynamic role of chromatin and covalent modifcation in transcription. Int. J. Biochem. Cell Biol. 41, 155-163 (2009).
10. Pettersson, K., Delaunay, F. & Gustafsson, J.A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 19, 4970-4978 (2000).
11. Lindberg, M.K. et al. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, Supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol. Endocrinol. 17, 203-208 (2003).
12. Monroe, D.G., Secreto, F.J., Subramaniam, M., Getz, B.J., Khosla, S. & Spelsberg, T.C. Estrogen receptor alpha and beta heterodimers exert unique efects on estrogen-and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol. Endocrinol. 19, 1555-1568 (2005).
13. Helguero, L.A., Faulds, M.H., Gustafsson, J.A. & Haldosén, L.A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) diferentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24, 6605-6616 (2005).
14. Simpson, E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 86, 225-230 (2003).
15. Smith, E.P. et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J. Clin. Endocrinol. Metab. 93, 3088-3096 (2008).
16. Zirilli, L., Rochira, V., Diazzi, C., Cafagni, G. & Carani, C. Human models of aromatase defciency. J. Steroid Biochem. Mol. Biol. 109, 212-218 (2008).
17. Koshla, S. Estrogen and bone: insights from estrogen-resistant, Aromatase-defcient, And normal men. Bone 43, 414-417 (2008).
18. Vandenput, L. & Ohlsson, C. Estrogens as regulators of bone health in men. Nat. Rev. Endocrinol. 5, 437-443 (2009).
19. Oz, O.K. et al. Bone phenotype of the aromatase defcient mouse. J. Steroid Biochem. Mol. Biol. 79, 49-59 (2001).
20. Harris, H.A., Katzenellenbogen, J.A. & Katzenellenbogen, B.S. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, In estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 143, 4172-4177 (2002).
21. Hillisch, A. et al. Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol. Endocrinol. 18, 1599-1609 (2004).
22. Hertrampf, T., Seibel, J., Laudenbach, U., Fritzemeier, K.H. & Diel, P. Analysis of the efects of oestrogen receptor alpha (ERalpha)-and ERbeta-selective ligands given in combination to ovariectomized rats. Br. J. Pharmacol. 153, 1432-1437 (2008).
23. The Women's Health Initiative Steering Committee. Efects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 291, 1701-1712 (2004).
24. Gennari, L. Lasofoxifene, A new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin. Pharmacother. 10, 2209-2220 (2009).
25. Kung, A.W., Chu, E.Y. & Xu, L. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis. Expert Opin. Pharmacother. 10, 1377-1385 (2009).
26. Carr, M.C. The emergence of the metabolic syndrome with menopause. J. Clin. Endocrinol. Metab. 88, 2404-2411 (2003).
27. Mendelsohn, M.E. & Karas, R.H. HRT and the young at heart. N. Engl. J. Med. 356, 2639-2641 (2007).
28. Mafei, L. et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: efects of testosterone, Alendronate, And estradiol treatment. J. Clin. Endocrinol. Metab. 89, 61-70 (2004).
29. Sudhir, K. et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96, 3774-3777 (1997).
30. Jones, M.E., Boon, W.C., McInnes, K., Mafei, L., Carani, C. & Simpson, E.R. Recognizing rare disorders: aromatase defciency. Nat. Clin. Pract. Endocrinol. Metab. 3, 414-421 (2007).
31. Hodgin, J.B. & Maeda, N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 143, 4495-4501 (2002).
32. Egan, K.M. et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306, 1954-1957 (2004).
33. Rayner, K. et al. Heat shock protein 27 protects against atherogenesis via an estrogen-dependent mechanism: role of selective estrogen receptor beta modulation. Arterioscler. Thromb. Vasc. Biol. 29, 1751-1756 (2009).
34. Gillies, G.E. & Mcarthur, S. Estrogen actions in the brain and the basis for diferential action in men and women: a case for sex-specifc medicines. Pharmacol. Rev. 62, 155-198 (2010).
35. Osterlund, M.K. Underlying mechanisms mediating the antidepressant efects of estrogens. Biochim. Biophys. Acta 1800, 1136-1144 (2010).
36. Brann, D.W., Dhandapani, K., Wakade, C., Mahesh, V.B. & Khan, M.M. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 72, 381-405 (2007).
37. Azcoitia, I., Sierra, A., Veiga, S., Honda, S., Harada, N. & Garcia-Segura, L.M. Brain aromatase is neuroprotective. J. Neurobiol. 47, 318-329 (2001).
38. Meltser, I. et al. Estrogen receptor beta protects against acoustic trauma in mice. J. Clin. Invest. 118, 1563-1570 (2008).
39. Vegeto, E., Benedusi, V. & Maggi, A. Estrogen anti-infammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 29, 507-519 (2008).
40. Tiwari-Woodruf, S. & Voskuhl, R.R. Neuroprotective and anti-infammatory efects of estrogen receptor ligand treatment in mice. J. Neurol. Sci. 286, 81-85 (2009).
41. Carroll, J.C. & Pike, C.J. Selective estrogen receptor modulators diferentially regulate alzheimer-like changes in female 3xTg-aD mice. Endocrinology 149, 2607-2611 (2008).
42. Kishi, Y. et al. Estrogen promotes diferentiation and survival of dopaminergic neurons derived from human neural stem cells. J. Neurosci. Res. 79, 279-286 (2005).
43. Deecher, D.C. & Dorries, K. Understanding the pathophysiology of vasomotor symptoms (hot fushes and night sweats) that occur in perimenopause, Menopause, And postmenopause life stages. Arch. Womens. Ment. Health 10, 247-257 (2007).
44. Opas, E.E. et al. Control of rat tail skin temperature regulation by estrogen receptor-beta selective ligand. Maturitas 64, 46-51 (2009).
45. Grady, D. et al. MF101, A selective estrogen receptor beta modulator for the treatment of menopausal hot fushes: a phase II clinical trial. Menopause 16, 458-465 (2009).
46. Nilsson, S. & Gustafsson, J.A. Biological role of estrogen and estrogen receptors. Crit. Rev. Biochem. Mol. Biol. 37, 1-28 (2002).
47. Hartman, J., Ström, A. & Gustafsson, J.A. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids 74, 635-641 (2009).
48. Treeck, O., Lattrich, C., Springwald, A. & Ortmann, O. Estrogen receptor beta exerts growth-inhibitory efects on human mammary epithelial cells. Breast Cancer Res. Treat. 120, 557-565 (2010).
49. Hegele-Hartung, C. et al. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc. Natl. Acad. Sci. USA 101, 5129-5134 (2004).
50. McPherson, S.J. et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc. Natl. Acad. Sci. USA 107, 3123-3128 (2010).